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Abstract 21  
There is evidence to suggest that abnormal angiogenesis, inflammation, and fibrosis 22  
drive diabetic nephropathy (DN). However, there is no specific treatment to counteract these 23  
processes. We aimed to determine whether DIAVIT, a natural Vaccinium myrtillus (blueberry) 24  
and Hippophae Rhamnoides (sea buckthorn) extract, is protective in a model of type II DN. 25  
Diabetic db/db mice were administered DIAVIT in their drinking water for 14 weeks. We 26  
assessed the functional, structural, and ultra-structural phenotype of three experimental groups 27  
(lean+vehicle, db/db+vehicle, db/db+DIAVIT). We also investigated the angiogenic and 28  
fibrotic pathways involved in the mechanism of action of DIAVIT. Diabetic db/db mice 29  
developed hyperglycaemia, albuminuria, and an increased glomerular water permeability; the 30  
latter two were prevented by DIAVIT. db/db mice developed fibrotic glomeruli, endothelial 31  
insult, and glomerular ultra-structural changes, which were not present in DIAVIT-treated 32  
mice. Vascular endothelial growth factor A (VEGF-A) splicing was altered in the db/db kidney 33  
cortex, increasing the pro-angiogenic VEGF-A165 relative to the anti-angiogenic VEGF-A165b. 34  
This was partially prevented with DIAVIT treatment. Delphinidin, an anthocyanin abundant in 35  
DIAVIT, increased the VEGF-A165b expression relative to total VEGF-A165 in cultured 36  
podocytes through phosphorylation of the splice factor SRSF6. DIAVIT, in particular 37  
delphinidin, alters VEGF-A splicing in type II DN, rescuing the DN phenotype. This study 38  
highlights the therapeutic potential of natural drugs in DN through the manipulation of gene 39  
splicing and expression. 40  
Keywords: diabetic nephropathy, fibrosis, albuminuria, permeability, VEGF-A 41  
 42  
 43  
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Introduction 44  
Diabetic nephropathy (DN) is the leading cause of end stage renal disease (ESRD) in 45  
the USA and across the world, affecting 50% of diabetic patients [1-3]. Glycaemic control, 46  
lipid and blood pressure control, plus renin-angiotensin-aldosterone system (RAAS) blockade 47  
are the current treatments of choice [4], but many DN patients still progress to ESRD. 48  
Therefore, novel therapeutic approaches for the treatment of DN are required. 49  
In DN, alterations of the glomerular filtration barrier (GFB) result in increased 50  
permeability to protein; such changes include glomerular basement membrane (GBM) 51  
thickening, mesangial matrix expansion (MME), podocyte detachment, and glomerular 52  
endothelial cell damage [5,6]. An increasing number of studies suggest that angiogenesis, 53  
inflammation, and fibrosis are responsible for the onset of type II DN [7,8]. Abnormal 54  
expression of vascular endothelial growth factor A (VEGF-A) in the kidney has been widely 55  
reported in DN [9-10]. Alternative splicing of exon 8 of VEGF-A results in an anti-angiogenic 56  
splice isoform, VEGF-A165b [11], which is protective in DN and renal disease [7,12]. In 57  
addition, activation of the transcription factor p65 nuclear factor kappa B (p65-NFĸB) is linked 58  
to the regulatory pathways that underlie the pro-inflammatory and pro-fibrotic response [13], 59  
and an increase in p65-NFĸB translocation to the nucleus has been shown in human DN [14]. 60  
In diabetes, glucotoxicity results in the generation of free radicals and oxidative stress, 61  
leading to the progression of diabetic complications [15]. Activation of NFĸB is widely 62  
reported to be evoked by increased oxidative stress [16]. Previous studies in rodent models of 63  
DN have indicated that a reduction in oxidative stress using anti-oxidants, such as those found 64  
in red berry extracts, resulted in decreased NFĸB activity, thus improving kidney function 65  
[17,18]. Other studies have also found that berry/polyphenol rich extracts protect against 66  
fibrosis, angiogenesis, and inflammation in the kidneys of diabetic animal models [19-21].  67  
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DIAVIT is a natural drug based on polyphenol-rich blueberry (Vaccinium myrtillus) 68  
and sea buckthorn (Hippophae Rhamnoides), which has been approved as an adjunct therapy 69  
for diabetes in Romania. DIAVIT contains approximately 10 mg anthocyanins per gram, which 70  
have been previously described to decrease vessel permeability, improve microcirculation and 71  
exert antioxidant activity [22,23]. The most abundant is delphinidin, which has been previously 72  
reported to have potent anti-angiogenic properties through the inhibition of PI3K/Akt/mTOR 73  
signaling pathways [24,25]. 74  
The aim of the present study was to test the hypothesis that DIAVIT would have a 75  
beneficial effect on the phenotype of diabetic renal lesions in the db/db mouse model of type 76  
II DN. Furthermore, we aimed to determine by which mechanism DIAVIT was exerting a 77  
protective effect by investigating pathways linked to the pro-angiogenic and pro-fibrotic 78  
response, as well as assessing the mechanistic effect of the most abundant anthocyanin present 79  
in DIAVIT, delphinidin, on the expression and splicing of VEGF-A. 80  
 81  
Materials and methods 82  
Ethics approval 83  
All experiments and procedures were approved by the UK Home office in accordance 84  
with the Animals (Scientific Procedures) Act 1986, and the Guide for the Care and Use of 85  
Laboratory Animals was followed.  86  
Administration of DIAVIT 87  
DIAVIT tablets (1 g) were obtained from Plantarom Laboratories, Cluj, Romania (Lot: 88  
01, Expiry: January 2017). One tablet was ground to a fine powder and dissolved into 250 ml 89  
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of drinking water. This dose was equivalent to the highest recommended daily dose of DIAVIT 90  
per kg body weight in patients, which equated to approximately 6 g/kg/day. The water was 91  
changed three times weekly. Lean and non-diabetic db/db mice consumed approximately 5 ml 92  
water per day, whereas diabetic mice consumed up to 60 ml per day, depending of the severity 93  
of diabetes. Information regarding the extract dosage of DIAVIT can be found in Table 1. We 94  
performed gas chromatography and mass spectrometry (GC-MS) to determine the complex 95  
chemical composition of the extract (S1 Fig). A large part of the extract in the DIAVIT tablets 96  
are dried blueberries from Romania – the composition of the extracts from these blueberries, 97  
especially anthocyanins content, has been extensively analysed before [26, 27]. 98  
 99  
Table 1. Dietary dosage of DIAVIT 100  
DIAVIT composition Per tablet (mg) Daily dosage (g/kg) 
Vaccinium myirtillus 392 2.35 
Hippophae rhamnoides 167 1.00 
 101  
 102  
Animal functional studies 103  
Male BKS.Cg-+Leprdb/+Leprdb/OlaHsd (db/db; obtained from Envigo) and lean 104  
control mice were obtained from Envigo (UK) (5 weeks; 25-49 g). Blood glucose was measured 105  
via blood collection from the tail vein, which was applied to an ACCU-CHEKâ strip (ACCU-106  
CHEKâ, Roche) to determine the concentration in mmol/l. Mice were deemed diabetic if they 107  
had two consecutive blood glucose readings >15 mmol/l taken 48 h apart. Baseline urine, 108  
weight, and blood glucose measurements were taken at 6 weeks of age, and DIAVIT 109  
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administration into the drinking water began immediately after. Urine collection, blood glucose 110  
measurement, and animals weights were done every week up until 20 weeks of age (week 14 111  
of experiment), when they were killed. There were three groups of mice; lean (n=6), db/db 112  
(n=9), and db/db treated with DIAVIT (n=9). Statistical power calculations showed that six 113  
control and eight experimental mice were needed to see a statistical difference in the functional 114  
phenotype (p>0.05) with a power value of 0.80 (>80%). 115  
 The urinary albumin creatinine ratio (uACR) was used as a measure of protein loss in 116  
the urine. Albumin was quantified with an albumin ELISA (Bethyl Laboratories, Inc), and 117  
creatinine with an enzymatic spectrophotometric assay (Creatinine Companion, Exocell). 118  
Assays were repeated in triplicate for each time point. Upon culling of mice via cervical 119  
dislocation, blood was collected for plasma creatinine measurements (Creatinine Companion, 120  
Exocell). Kidneys were removed and part of the cortex was immediately diced into 1 mm3 121  
pieces and fixed in 2.5% gluteraldehyde in 0.1 M cacodylate buffer for electron microscopy 122  
(EM). Pieces of kidney cortex were also fixed in 4% paraformaldehyde (PFA), snap frozen in 123  
embedding medium (OCT), and snap frozen in liquid nitrogen before storing at -80°C for RNA 124  
and protein analysis at a later date. The remaining kidney was used to harvest glomeruli, using 125  
a standard sieving technique, for use an oncometric assay to determine the glomerular water 126  
permeability normalised to glomerular area (LpA/Vi) of individual glomeruli ex vivo [28]. 127  
LpA/Vi experiments were carried out on 6 mice per group, 3-5 glomeruli per mouse. 128  
Structural and ultra-structural phenotype 129  
PFA-fixed kidney cortex was sectioned at 5 µm thickness and stained with Periodic 130  
Acid Schiff (PAS) and Masson’s Trichrome Blue stain (both Sigma). Sections were imaged on 131  
a light microscope and experiments were repeated three times on 4 mice per group. 132  
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 The ultra-structural phenotype was determined by post-fixation of the glutaraldehyde-133  
fixed diced kidney cortex with 1% osmium tetroxide, before embedding in Araldite (Agar 134  
Scientific). Sections were cut at 50-100nm thickness and stained with 3% aqueous uranyl 135  
acetate and Reynolds’ lead citrate solution. After images were taken, detailed measurements of 136  
the filtration barrier were taken by a blinded experimenter at random points using ImageJ. 137  
Measurements included GBM width, number of endothelial fenestrations and podocyte foot 138  
processes per µm length, and average podocyte foot process width. We also assessed whether 139  
there was evidence of glomerular MME. 140  
Cell culture studies 141  
Mycoplasma-free immortalized human podocytes (hTERT; Evercyte) were plated in to 142  
12-well plates before treating for 48 hrs with DIAVIT (1 mg/ml in 1xPBS) or delphinidin 143  
chloride (Sigma Aldrich) (10 µg/ml in DMSO). A dosage of 1 mg/ml DIAVIT was chosen 144  
because this equated to an anthocyanin concentration of approximately 10 µg/ml, of which 145  
delphinidin is the most abundant in the extract, which has been shown to have anti-angiogenic 146  
properties in previous studies [25].  147  
To determine the effect of delphinidin on the phosphorylation of SR proteins, podocytes 148  
were serum starved for 2 hrs before treating with delphinidin chloride (10 µg/ml), or DMSO 149  
control for a further 2 hrs. Cells were then stimulated with a diabetic soup (30 mM Glucose, 1 150  
ng/ml TNFα, 1 ng/ml IL-6, and 100 nM insulin) or an osmotic control (5mM Glucose + 25 151  
mM Mannitol) for 0.5 or 1 hrs, before extracting the protein. 152  
Matrigel angiogenesis assay 153  
Podocytes were treated with either DIAVIT (1 mg/ml) or DIAVIT plus anti-VEGF-154  
A165b (1 µg/ml), or delphinidin chloride (10 µg/ml) or delphinidin plus anti-VEGF-A165b (1 155  
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µg/ml) for 48 hrs. IgG was added to controls. The conditioned media was then used to treat 156  
human umblical vein endothelial cells (HUVECs) plated onto Matrigel. The wells were imaged 157  
4 hrs later and the tubule length and number of branch points were quantified. 158  
Immunofluorescence 159  
Frozen kidney cortex was sectioned at 5 µm thickness, mounted on to glass slides, and 160  
fixed for 10 min with 4% PFA before washing in PBS. Sections were blocked with 3% bovine 161  
serum albumin (BSA) and 5% normal goat serum in PBS for 1 hr before incubating with the 162  
primary antibody (anti-collagen IV or anti-fibronectin, 1:100, Abcam; anti-nephrin, 1:250, 163  
Acris; anti-podocin, 1:250, Sigma; anti-PECAM-1, 1:100, BD Bioscience) diluted in 3% BSA 164  
in PBS at 4°C overnight. After washing in PBS, the appropriate fluorescent secondary antibody 165  
was used (Alexa Fluor) in 3% BSA in PBS for 2 hr at room temperature. Sections were then 166  
washed in PBS before staining with DAPI and mounting with coverslips. Glomeruli and cortex 167  
were imaged using a fluorescent microscope. Experiments were repeated three times on 3-4 168  
mice per group. 169  
Western blotting 170  
Denatured protein samples were run on mini-PROTEAN® TGX Stain Free™ pre-cast 171  
gels (4-15%, BIORAD), which allow for visualisation and accurate analysis of the total protein 172  
loaded for each sample using a Gel-Docä EZ (BIO-RAD) imaging system. The use of this 173  
system means a housekeeping protein loading control is not required as the amount of protein 174  
on the membrane for each sample can be quantified. Once protein had been transferred on to a 175  
PVDF membrane, total protein could be quantified. Membranes were blocked in 3% BSA in 176  
TBS plus 0.3% Tween before being probed with either anti-collagen IV (Abcam), anti-177  
fibronectin (Abcam), anti-nephrin, Acris), anti-podocin (Sigma), anti-VEGF receptor 2 178  
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(VEGFR2) (Cell Signalling), anti-VEGF A20 (Santa Cruz), anti-mVEGF-A165b (Prof Kenneth 179  
Walsh, Boston University), anti-phospho-AktSer473 (Cell Signalling), anti-Akt (Cell Signalling), 180  
anti-phospho-extracellular signal-related kinase 1/2 (ERK1/2) (Cell Signalling), anti-ERK1/2 181  
(Cell Signalling), anti- cyclooxygenase 2 (COX-2) (Cell Signalling), anti-wilms tumor 1 182  
(WT1) (Abcam), anti-p65-nuclear factor kappa B (NFĸB) (Cell Signalling), anti-SR proteins 183  
1H4 (Santa Cruz), and anti-phospho-SR proteins (mab104), all at 1:1000 dilution in 3% BSA-184  
TBS-Tween (0.3%), at 4°C overnight. After washing membranes in TBS-Tween (0.3%), HRP-185  
conjugated secondary antibodies were diluted in 3% BSA-TBS-Tween (0.3%), 1:10,000. 186  
Membranes were washed again and imaged using ECL detection agent (BIO-RAD) on an 187  
Amersham imager. The protein of interest was then normalised to the total protein loaded for 188  
each sample, as quantified by the Gel-Docä EZ imaging system (BIO-RAD). Experiments 189  
were repeated on at least three biological repeats, with the relative controls run on the same 190  
blot. 191  
Statistical analysis 192  
We performed statistical analysis using GraphPad Prism software. Data was tested for 193  
normality and either a one-way or two-way ANOVA was used to analyse data sets. Post-hoc 194  
analysis was then carried out using the Bonferroni test for comparison between pairs. All results 195  
are presented as the average ± standard error of the mean (SEM). Imaging and analysis was 196  
blinded to the researcher to restrict bias. Details of biological and technical repeats can be found 197  
in the methods section. P values <0.05 were considered statistically significant. Throughout 198  
the manuscript, * indicates a significant different between lean mice and db/db mice and † 199  
indicates a significant difference between db/db mice and db/db + DIAVIT mice, as determined 200  
by a one-way ANOVA with Bonferroni post-hoc test. 201  
 202  
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Results 203  
DIAVIT is protective against diabetes-induced increases in 204  
glomerular water permeability and albuminuria 205  
Both db/db and db/db + DIAVIT mice developed and maintained a significant increase 206  
in their blood glucose levels one week after beginning of the study, compared to lean controls 207  
(Fig 1A; blood glucose averaged over 14 weeks: 8.29 ± 0.08, 24.54 ± 1.23, and 21.83 ± 1.28 208  
mmol/l in lean, db/db, and db/db + DIAVIT mice, respectively). There was no significant 209  
difference in blood glucose levels between the db/db and db/db + DIAVIT groups. However, 210  
DIAVIT treatment did prevent the progressive increase in albuminuria observed in db/db mice 211  
(Fig 1B; uACR (µg/mg) at 14 weeks: lean, 12.8 ± 1.2 µg/mg; db/db, 312.3 ± 154.4 µg/mg; 212  
db/db + DIAVIT, 138.7 ± 19.4 µg/mg; values normalized to baseline shown in S2 Fig). 213  
Furthermore, the water permeability of individual glomeruli ex vivo was significantly increased 214  
in db/db mice after 14 weeks of elevated blood glucose compared to lean controls (Fig 1C; 215  
*p<0.05). This was significantly prevented in db/db + DIAVIT glomeruli (†p<0.05). Although 216  
db/db mice developed type II diabetes and albuminuria, no changes in the plasma creatinine 217  
levels were observed (Fig 1D). Therefore, DIAVIT protected against increases in glomerular 218  
water permeability and albuminuria in type II diabetic mice without altering glycaemia. 219  
 220  
Fig 1. DIAVIT prevents albuminuria and increased glomerular water permeability in 221  
diabetic db/db mice, whilst having no effect on blood glucose  222  
A) db/db mice develop increased blood glucose at 6-7 weeks of age (week 1 of treatment), 223  
compared to lean controls (*p<0.05), which is not affected by DIAVIT consumption (ns; 224  
p>0.05; n=6-9 mice; Two-way ANOVA based on the average values over 14 weeks). B) When 225  
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assessing the urinary albumin creatinine ratio (uACR), db/db mice develop progressive 226  
albuminuria at 10 weeks of age (week 4 of treatment), compared to lean controls (*p<0.05), 227  
which is significantly rescued by DIAVIT (†p<0.05; n=6-9 mice; Two-way ANOVA based on 228  
the average values over 14 weeks). C) Glomeruli from db/db mice have an increased 229  
glomerular water permeability (LpA/Vi) when compared to lean control glomeruli (*p<0.05), 230  
which is significantly rescued in glomeruli from DIAVIT-treated db/db mice (†p<0.05; n=6 231  
mice, 15-25 glomeruli; One-way ANOVA with Bonferroni post-hoc test for comparison 232  
between pairs). D) Plasma creatinine levels remained unchanged between groups (ns; p>0.05; 233  
n=6-9 mice; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs). 234  
 235  
DIAVIT prevents the development of diabetes-induced renal 236  
fibrosis 237  
After 14 weeks of DIAVIT treatment the structural phenotype was assessed. PAS 238  
staining indicated some MME and the development of vacuoles within the glomeruli of db/db 239  
mice (Fig 2A), which appeared to be reduced when db/db mice had been treated with DIAVIT. 240  
In addition, Trichrome blue staining showed an increase in collagen (blue) deposition in the 241  
glomeruli and cortex of db/db kidneys (Fig 2A), which also appeared to be reduced in db/db + 242  
DIAVIT mice. To quantify the extent of glomerular fibrosis, we carried out 243  
immunofluorescence for collagen IV and fibronectin; two proteins highly expressed in a 244  
fibrotic kidney (Figure 2A). Both collagen IV and fibronectin expression were increased in the 245  
glomeruli of diabetic db/db mice compared to lean controls (Fig 2B; *p<0.05). However, they 246  
were significantly reduced in DIAVIT-treated db/db glomeruli (†p<0.05). 247  
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 The increase in kidney fibrosis observed in db/db mice was further assessed by Western 248  
blotting of kidney cortex proteins for collagen IV and fibronectin. The relative expression of 249  
both proteins was increased in db/db kidneys compared to lean controls (*p<0.05), which was 250  
significantly prevented in db/db + DIAVIT kidneys (†p<0.05) (Fig 2C-E). Therefore, DIAVIT 251  
protects against renal fibrosis in a type II model of diabetes. 252  
 253  
Fig 2. Diabetic db/db mice develop glomerular fibrosis, which is prevented in DIAVIT 254  
treated db/db mice  255  
A) Periodic Acid Schiff (PAS) staining indicated structural abnormalities in db/db glomeruli, 256  
including mesangial matrix expansion and the presence of vacuoles (scale bar 40 µm). These 257  
appeared to be less frequent in DIAVIT-treated db/db glomeruli. Trichrome blue staining 258  
showed an increase in fibrosis (blue collagen staining) in the db/db kidney cortex, which was 259  
lower in the DIAVIT-treated db/db kidneys (scale bar 40 µm). More specifically, 260  
immunofluorescence for collagen IV and fibronectin showed an increase in glomerular fibrosis 261  
in db/db mice, compared to lean controls, which was prevented by DIAVIT treatment of the 262  
diabetic mice (quantified in B; *p<0.05 lean vs db/db; †p<0.05 db/db vs db/db + DIAVIT; n=4 263  
mice; 15-20 glomeruli per mouse; One-way ANOVA with Bonferroni post-hoc test for 264  
comparison between pairs; scale bar is 40 µm). C) Western blotting of protein from the kidney 265  
cortex confirms an increase in the protein expression of collagen IV and fibronectin in db/db 266  
mice, which is prevented with DIAVIT treatment. Analysis of the Western blots is summarised 267  
in D and E (*p<0.05 lean vs db/db; †p<0.05 db/db vs db/db + DIAVIT; n=3-4 mice; One-way 268  
ANOVA with Bonferroni post-hoc test for comparison between pairs). 269  
 270  
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DIAVIT protects against the endothelial damage caused by type II 271  
diabetes 272  
In order to assess how DIAVIT is protective in type II DN, we determined the 273  
expression of podocyte and endothelial-specific proteins as markers of cell function/loss. 274  
Immunofluorescence for the podocyte markers nephrin and podocin indicated no changes in 275  
the expression of these two proteins in any of the groups (Fig 3A); therefore, suggesting no 276  
podocyte loss. This was further confirmed by Western blotting of protein from the kidney 277  
cortex (Fig 3B and C). 278  
 Immunofluorescence for the endothelial marker PECAM-1 showed reduced expression 279  
in db/db glomeruli relative to lean controls (Fig 3D and E; *p<0.05). This was significantly 280  
prevented in db/db + DIAVIT glomeruli (†p<0.05). Further evidence for endothelial loss in 281  
db/db glomeruli was indicated by reduced protein expression of VEGFR2 in the cortex of db/db 282  
mice, as assessed by Western blotting, relative to lean controls (Fig 3F and G;*p<0.05). The 283  
reduction in VEGFR2 expression was prevented, and even significantly increased relative to 284  
controls in the db/db + DIAVIT kidney cortex (†p<0.05). Therefore, DIAVIT prevented the 285  
type II diabetes-induced reduction in renal endothelial markers. 286  
 287  
Fig 3. Diabetic db/db mice develop an endothelial insult, which is prevented by DIAVIT 288  
treatment of diabetic db/db mice  289  
A) Immunofluorescence for nephrin and podocin showed no change in the expression of these 290  
podocyte markers between all groups (n=4 mice; scale bar 40 µm). This was confirmed by 291  
Western blotting of protein extracted from the kidney cortex (B); analysis is summarised in (C) 292  
(ns; p>0.05; n=3-4 mice; One-way ANOVA with Bonferroni post-hoc test for comparison 293  
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between pairs). D) Immunofluorescence for the endothelial marker PECAM-1 showed a 294  
reduction in PECAM-1 expression in db/db glomeruli, which was prevented when db/db mice 295  
were treated with DIAVIT; analysis shown in (E) (*p<0.05 lean vs db/db; †p<0.05 db/db vs 296  
db/db + DIAVIT; n=3-4 mice; 14-20 glomeruli per mouse; One-way ANOVA with Bonferroni 297  
post-hoc test for comparison between pairs; scale bar 40 µm). F) Western blotting for the 298  
endothelial marker VEGF receptor 2 (VEGFR2) showed a decrease in the db/db kidney cortex, 299  
further indicating endothelial loss, which was prevented, and even increased relative to 300  
controls, in DIAVIT-treated db/db mice. Analysis is shown in (G) (*p<0.05 lean vs db/db; 301  
†p<0.05 lean and db/db vs db/db + DIAVIT; n=3-4 mice; One-way ANOVA with Bonferroni 302  
post-hoc test for comparison between pairs). 303  
 304  
DIAVIT protects against ultra-structural changes 305  
We investigated the glomerular ultra-structural phenotype using EM. In diabetic db/db 306  
mice, there was evidence of MME, which was not apparent in db/db + DIAVIT glomeruli (Fig 307  
4A). In addition, db/db mice developed an increased GBM width, loss of endothelial 308  
fenestrations, reduced number of podocyte foot processes, and an increased podocyte foot 309  
process width (Fig 4B-E; *p<0.05). However, in db/db + DIAVIT glomeruli, the diabetes-310  
induced changes in the GBM, number of endothelial fenestrations, and podocyte foot process 311  
width were prevented (†p<0.05). Therefore, DIAVIT protects against diabetes-induced 312  
glomerular ultra-structural changes. 313  
 314  
Fig 4. DIAVIT protects against diabetes-induced glomerular ultra-structural changes  315  
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A) Representative glomerular electron micrographs from lean, db/db, and db/db + DIAVIT 316  
mice. Diabetic db/db glomeruli shows evidence of MME, which is not apparent in lean or db/db 317  
+ DIAVIT glomeruli. Diabetic db/db glomeruli developed an increased GBM width (B), 318  
decreased number of endothelial fenestrations (C) and podocyte foot processes (D) per µm 319  
length, and an increased average podocyte foot process width (E) compared to lean controls 320  
(*p<0.05 vs lean). DIAVIT prevented the changes to the GBM width (B), number of 321  
endothelial fenestrations per µm length (c), and average podocyte foot process width (E) in 322  
db/db + DIAVIT glomeruli (†p<0.05 vs db/db). DIAVIT had no effect on the podocyte foot 323  
processes per µm length (D) (*p<0.05 vs lean) (n=3 mice; One-way ANOVA with Bonferroni 324  
post-hoc test for comparison between pairs).  325  
 326  
DIAVIT alters VEGF-A splicing 327  
We assessed the protein expression of VEGF-A, which is also highly implicated in DN, 328  
and the alternatively spliced anti-angiogenic isoform VEGF-A165b. Treatment of conditionally 329  
immortalized podocytes with DIAVIT (1 mg/ml) for 48 hrs resulted in a splicing switch to 330  
increase the protein expression of VEGF-A165b relative to total VEGF-A165 (Fig 5A, quatified 331  
in Fig 5Bi; *p<0.05), with no effect on pan-VEGF-A expression (Fig 5Bi). We also saw a 332  
significant increase in the VEGF-Axxxb/VEGF-Axxx ratio at the mRNA level via RT-PCR, 333  
quantified using a bioanalyzer (Fig 5C). Therefore, we assessed the effects of DIAVIT on 334  
angiogenesis using a Matrigel angiogenesis assay. HUVECs were plated onto Matrigel and 335  
treated with conditioned media from podocytes pre-treated with DIAVIT for 48 hrs. Four hours 336  
later, DIAVIT-treated HUVECs had a reduction in the relative number of branch points and 337  
the relative tubule length (Fig 5D and E; *p<0.05), compared to untreated controls. This anti-338  
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angiogenic effect was significantly reversed when the podocytes and HUVECs were treated 339  
with DIAVIT and an antibody specific for the VEGF-A165b isoform (†p<0.05). 340  
 When analyzing the splicing pattern of VEGF-A in the kidney cortex of diabetic db/db 341  
mice, there was a significant increase in the relative expression of VEGF-A120, which was not 342  
observed in DIAVIT-treated db/db mice (Fig 5F and G; *p<0.05). An increase in the expression 343  
of VEGF-A164 (which corresponds to human VEGF-A165) was also observed in both diabetic 344  
groups relative to lean controls (*p<0.01). No changes in the expression of VEGF-A188 was 345  
observed in either group. When looking specifically at the splicing VEGF-A164, the anti-346  
angiogenic VEGF-A165b (alternatively spliced isoform of VEGF-A164) was down-regulated in 347  
the db/db kidney cortex relative to lean controls (*p<0.05). This was partially prevented when 348  
the db/db mice were treated with DIAVIT (†p<0.05). Therefore, DIAVIT switches VEGF-349  
A165/164 splicing to increase the anti-angiogenic VEGF-A165b isoform. 350  
The expression of the transcription factor WT1, which promotes VEGF-A165b splicing 351  
[25], remains unchanged in the kidney cortex in diabetic db/db mice relative to controls; 352  
however, DIAVIT treatment induced a significant increase in WT1 expression (Fig 5H and I; 353  
relative expression: db/db + DIAVIT, *p<0.05). 354  
 355  
Fig 5. DIAVIT alters VEGF-A splicing to increase VEGF-A165b  356  
A) DIAVIT treatment (1 mg/ml) of podocytes for 48 hrs resulted in an increased protein 357  
expression of VEGF-A165b relative to total VEGF-A165 (quantified in B; *p<0.05; n=3 358  
biological repeats; T-test; A – the same blot was first probed with VEGF-A165b before stripping 359  
and reprobing with panVEGF-A). C) This switch in splicing to increase the VEGF-360  
Axxxb/VEGF-Axxx ratio was also observed at the mRNA level (*p<0.05; n=4 biological repeats;   361  
T-test). D) DIAVIT inhibited angiogenesis in HUVECs when plated on to Matrigel (*p<0.05 362  
   17  
vs control), which was partially prevented when an antibody specific for VEGF-A165b was 363  
added to the treatment (†p<0.05 vs DIAVIT). Measurments were taken in the form of the 364  
relative number of branch points (Ei) and the relative tubule length (Eii) (n=4; One-way 365  
ANOVA with Bonferroni post-hoc test for comparison between pairs). F) Diabetic db/db mice 366  
showed switches in the spicing of VEGF-A in the kidney cortex; VEGF-A120 and VEGF-A164 367  
were increased relative to lean controls (Gi; *p<0.05 and *p<0.01, VEGF-A120 and VEGF-368  
A164, respectively; all VEGF-A isoforms were detected on the same blot), whereas VEGF-A165b 369  
was down-regulated (Gii; *p<0.05). Treatment of the diabetic mice with DIAVIT resulted in 370  
no significant increases in VEGF-A120 (Gi); although no effect was observed on total VEGF-371  
A164 expression compared to un-treated db/db mice, DIAVIT did cause a shift in splicing to 372  
up-regulate VEGF-A165b relative to VEGF-A164 (Gii; †p<0.05 vs diabetic; n=3-6 mice; One-373  
way ANOVA with Bonferroni post-hoc test for comparison between pairs). H) Diabetes did 374  
not alter the expression of the podocyte marker and transcription factor WT1. However, 375  
DIAVIT did result in an increase in WT1 expression in the kidney cortex of db/db mice (I) 376  
(*p<0.05; n=4 mice; One-way ANOVA with Bonferroni post-hoc test for comparison between 377  
pairs). 378  
 379  
DIAVIT prevents the activation of pro-angiogenic and pro-fibrotic 380  
factors 381  
To further assess the effects of DIAVIT on the diabetic kidney, we looked at the 382  
activation of pro-angiogenic/permeability factors known to be involved in the progression of 383  
DN. We found the phosphorylation of AktSer473 and ERK1/2, normalized to total Akt and 384  
ERK1/2, respectively, to be increased in the kidney cortex of diabetic db/db mice (*p<0.01); 385  
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the relative expression of Akt, ERK1/2 and COX-2 was also increased (Fig 6a-d; *p<0.05). All 386  
of the above was prevented in diabetic db/db + DIAVIT mice (†p<0.05) (Fig 6A-D). 387  
We also assessed the effects of DIAVIT on the protein expression and activation of 388  
p65-NFĸB, which is involved in pro-fibrotic gene transcription [13]. In the db/db kidney 389  
cortex, after 14 weeks of diabetes, there was a significant increase in the protein expression of 390  
p65-NFĸB, relative to lean controls (Fig 6E and F; *p<0.05). This increase in p65-NFĸB was 391  
prevented by DIAVIT treatment of the diabetic db/db mice (†p<0.05).  392  
 393  
Fig 6. Diabetic mice develop an increase in the activation of pro-angiogenic and pro-394  
fibrotic factors in the kidney, which is prevented with DIAVIT treatment 395  
A) Western blotting of protein extracted from the kidney cortex shows an increased 396  
phosphorylation and expression of AktSer473 (A, B), an increase in the phosphorylation and 397  
expression of ERK1/2 (a, c), and an increase in the expression of COX-2 in diabetic db/db 398  
mice (A, D; phosphorylation *p<0.01; expression *p<0.05 vs lean). DIAVIT prevented the 399  
increased activation and expression of these factors in the diabetic mice (A-D; †p<0.05 vs 400  
diabetic; n=3-8 mice; ; all proteins were detected on the same blot). In addition,  diabetic db/db 401  
mice had an increased expression of  p65-NFĸB in the kidney cortex, which was singifcantly 402  
rescued by DIAVIT treatment (E, F; p<0.05; n=3-4 mice; One-way ANOVA with Bonferroni 403  
post-hoc test for comparison between pairs). 404  
 405  
Delphinidin alters the expression and splicing ratio of VEGF-A in 406  
podocytes 407  
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We further assessed the mechanistic effects of the most abundant anothocyanin in 408  
DIAVIT, delphinidin, on VEGF-A splicing and expression. Treatment of conditionally 409  
immortalized podocytes with delphinidin (10 µg/ml) for 48 hrs resulted in a splicing switch to 410  
increase VEGF-A165b relative to total VEGF-A165 in both normal glucose (NG) and high 411  
glucose (HG) conditions (protein: Fig 7A, quatified in Fig 7B; p<0.05; mRNA: Fig 7D). In 412  
addition, delphinidin significantly decreased the expression of total VEGF-A165 (Fig 7C; 413  
p<0.05). Therefore, we assessed the effects of delphinidin on angiogenesis using a Matrigel 414  
angiogenesis assay. HUVECs were plated onto Matrigel and treated with conditioned media 415  
from podocytes pre-treated with delphinidin for 48 hrs. Four hours later, delphinidin-treated 416  
HUVECs had a reduction in the relative number of branch points and the relative tubule length 417  
(Fig 7E and F; *p<0.05), compared to DMSO treated controls. This anti-angiogenic effect was 418  
not significantly reversed when the podocytes and HUVECs were treated with delphinidin and 419  
an antibody specific for the VEGF-A165b isoform. 420  
 To determine the mechanism of the effect of delphinidin on VEGF-A splicing, we 421  
analysed the phosphorylation of SRSF6 (resulting in VEGF-A165b expression) and SRSF1 422  
(resulting in VEGF-A165 expression) in NG and HG conditions. We found that after 60 min, 423  
delphinidin significantly increased the phosphorylation of SRSF6 in HG conditions (Fig 7G, 424  
quantified in Fig 7H; p<0.05). Delphinidin had no effect on the phosphorylation of SRSF1 in 425  
either condition. 426  
 427  
Fig 7. Delphinidin alters VEGF-A splicing to increase VEGF-A165b and decrease total 428  
VEGF-A expression 429  
A) Treatment of podocytes with delphinidin chloride (10 µg/ml) under normal glucose (NG; 5 430  
mM glucose + 25 mM mannitol) and high glucose (HG; 30 mM glucose, 1 ng/ml TNFα, 1 431  
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ng/ml IL-6, and 100 nM insulin) for 48 hrs increased the protein expression of VEGF-A165b 432  
relative to total VEGF-A165 (quantified in B; *p<0.05 vs NG, †p<0.05 vs HG; n=3 biological 433  
repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs; A – 434  
the same blot was first probed with VEGF-A165b before stripping and reprobing with 435  
panVEGF-A). C) Under both NG and HG condition, delphinidin significantly decreased the 436  
protein expression of total VEGF-A165 (*p<0.05; n=3 biological repeats; One-way ANOVA 437  
with Bonferroni post-hoc test for comparison between pairs). D) Analysis at the mRNA level 438  
shows an increase in the VEGF-Axxxb/VEGF-Axxx ratio after treatement with delphinidn 439  
(*p<0.05; n=4 biological repeats;  T-test). E) Delphinidin inhibited angiogenesis in HUVECs 440  
when plated on to Matrigel (*p<0.05 vs control). Addition of an antibody specific for VEGF-441  
A165b did not alter the effect of delphinidin. Measurments were taken in the form of the relative 442  
number of branch points (Fi) and the relative tubule length (Fii) (n=4; One-way ANOVA with 443  
Bonferroni post-hoc test for comparison between pairs). G) Cells pre-treated with 444  
DMSO/delphinidin were stimulated with NG/HG for 30 or 60 mins. After 30 min, there was 445  
no significant effect of delphinidin on the phosphorylation of SRSF6 or SRSF1 under either 446  
condition (H). After 60 min, delphinidin significantly increased the phosphorylation of SRSF6 447  
after stimulation with HG (*p<0.05 vs NG and HG controls; n=3 biological repeats; One-way 448  
ANOVA with Bonferroni post-hoc test for comparison between pairs). There was no 449  
significant effect on phospho-SRSF1 at 60 min. 450  
 451  
Discussion 452  
This study provides evidence that DIAVIT, a natural drug containing blueberry and sea 453  
buckthorn, is protective in a type II mouse model of DN. In this study, DIAVIT prevented the 454  
increased permeability of the GFB, fibrosis in the kidney cortex, and an endothelial insult in 455  
type II diabetic mice. Mechanistically, DIAVIT is likely to be affecting multiple pathways as 456  
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it is comprised of hundreds of compounds. However, with regards to 457  
microcirculation/permeability and fibrosis, DIAVIT switched the splicing of VEGF-A to 458  
increase the expression of the anti-angiogenic VEGF-A165b, and reduced the activation of pro-459  
inflammatory and pro-fibrotic markers. Furthermore, the most abundant anthocyanin in 460  
DIAVIT, delphinidin, was found to modulate VEGF-A expression and splicing through the 461  
activation of SRSF6. This resulted in an anti-angiogenic effect through up-regulation of the 462  
anti-angiogenic VEGF-A165b, but a reduction in the expression of total VEGF-A. 463  
With increasing evidence to suggest that DN is driven by microvessel damage and 464  
increased permeability, fibrosis, and inflammation, recent developments have focused on 465  
therapeutic factors that prevent the up-regulation of these pathways [7,17,18]. VEGF-A is 466  
widely accepted to be involved in the vascular complications related to diabetes; however, the 467  
alternative splice isoform VEGF-A165b has recently proven to be therapeutically beneficial in 468  
both type I and type II models of DN [7]. In addition, switches in VEGF-A splicing to up-469  
regulate the VEGF-Axxxb (xxx denotes the number of amino acids) isoforms have also been 470  
shown to have anti-angiogenic, and therefore therapeutic, effects in models of retinopathy and 471  
cancer [29,30]. To our knowledge, this is the first report to suggest an anthocyanin present in 472  
a natural drug can switch VEGF-A splicing to promote the expression of the anti-angiogenic 473  
VEGF-A165b both in the mouse kidney cortex and in conditionally immortalized podocytes. 474  
Over-expression of just the VEGF-A165b isoform in the podocytes of mice has no detrimental 475  
effects on kidney function [31]. Furthermore, over-expression of podocyte-specific VEGF-476  
A165b when all other isoforms of VEGF-A are depleted results in a rescue of the glomerular 477  
injury phenotype [12]. We show that in db/db mice the splicing and expression of VEGF-A are 478  
altered to increase the pro-angiogenic VEGF-A164 and decrease the anti-angiogenic VEGF-479  
A165b, which is consistent with what is reported in human diabetic nephropathy [7]. However, 480  
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DIAVIT partially prevents this switch in splicing, resulting in an increase in the VEGF-A-481  
165b/VEGF-A164 ratio in the diabetic mice (Fig 5E). We hypothesize that this switch in splicing 482  
contributed to the therapeutic phenotype induced by DIAVIT, including preventing increases 483  
in albuminuria and glomerular water permeability (Fig 1), glomerular fibrosis (Fig 2), and the 484  
ultra-structural changes to the mesangial cells, endothelial cells, GBM, and podocyte foot 485  
processes (Fig 4), which have previously been shown to be rescued by VEGF-A165b treatment 486  
in models of DN and kidney disease [7,12].  487  
VEGF-A165b has been reported to increase the glomerular endothelial cell VEGFR2 488  
expression [7,12]. We show a similar result; the kidney cortex expression of VEGFR2 is 489  
decreased in diabetic mice, which is rescued to expression levels higher than the lean controls 490  
in db/db + DIAVIT mice (Fig 3F). This is likely to be in part due to the increased expression 491  
of VEGF-A165b in the DIAVIT-treated mice. Although VEGF-A165b increases the expression 492  
of VEGFR2, it inhibits signalling by preventing receptor phosphorylation, as previously shown 493  
in HUVECs [30], and ciGEnCs [12]. As a result, the activation of pro-angiogenic and pro-494  
permeability proteins downstream of VEGFR2, such as Akt and ERK1/2, are inhibited. We see 495  
a similar result in this study; diabetic mice treated with DIAVIT have reduced phosphorylation 496  
and expression of Akt and ERK1/2 compared to diabetic controls (Fig 6A).  497  
Furthermore, activation of Akt has been previously reported to result in the auto-498  
phosphorylation of serine/threonine-protein kinase 1 (SRPK1), an SR protein kinase 499  
responsible for phosphorylating SRSF1, which promotes proximal splice site selection in exon 500  
8 of VEGF-A and thus increases the expression of the pro-angiogenic VEGF-Axxx isoforms 501  
[33]. WT1 is an inhibitor of SRPK1 phosphorylation; Denys Drash Syndrome patients have a 502  
mutation in WT1, resulting in no inhibition of SRPK1 and an increased VEGF-A165/VEGF-503  
A165b ratio [29]. However, the WT1-SRPK1 signaling pathway is not the only pathway known 504  
to regulate VEGF-A splicing; SRSF6, which promotes distal splice site selection in exon 8 of 505  
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VEGF-A (increasing VEGF-Axxxb expression) has recently been shown to be down-regulated 506  
in diabetes [34]. This may be explain why we do not see a change in WT1 expression in db/db 507  
mice relative to lean controls, even though the expression of VEGF-A165b is decreased in db/db 508  
mice. In our study, we see an increase in the phosphorylation of Akt within the kidney cortex 509  
of diabetic db/db mice, which is not observed in db/db + DIAVIT mice. Furthermore, we also 510  
see an increase in WT1 expression with DIAVIT treatment.  511  
Although there are no reports on delphinidin, or any other anothocyanins, having an 512  
effect on gene splicing, delphinidin is widely reported to reduce total VEGF-A expression 513  
through the PKC/PI3K/Akt/mTOR signaling pathways, without having any effect on the 514  
p38MAPK pathway [24,25]. Previous studies on VEGF-A splicing have shown that 515  
upregulation of the PKC pathway results in SRSF1 phosphorylation and proximal splice site 516  
selection in exon 8 of VEGF-A, whereas upregulation of the p38MAPK signalling pathways 517  
instead induces SRSF6 phosphorylation promoting distal splice site selection [35]. The present 518  
study confirms these findings at the level of VEGF-A splicing regulation; delphinidin induced 519  
the phosphorylation of SRSF6 but not SRSF1 in podocytes, resulting in an increase in VEGF-520  
A165b relative to VEGF-A165. Together, this data suggests that DIAVIT, including delphinidin 521  
present in DIAVIT, is increasing the VEGF-A165b/VEGF-A165 ratio through the inhibition of 522  
Akt, up-regulation of WT1, and increased phosphorylation of SRSF6. 523  
In addition, we show that delphinidin results in a down-regulation of pro-angiogenic 524  
VEGF-A expression, resulting in the inhibition of angiogenesis (Fig 7D), as reported in 525  
multiple studies assessing the effects of delphinidin on VEGF-A expression [24,25]. Although 526  
the anti-angiogenic effect of DIAVIT was reversed when anti-VEGF-A165b was added to the 527  
Matrigel assay, leading us to conclude that the total anti-angiogenic effect of DIAVIT was 528  
partially the result of alternative splicing, there was no significant reversal of the inhibition of 529  
angiogenesis by delphinidin with anti-VEGF-A165b. We clearly show that delphinidin 530  
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promotes VEGF-A165b expression relative to VEGF-A165; however, delphinidin also has an 531  
inhibitory effect on VEGF-A total expression, which is not observed in response to the DIAVIT 532  
extract. Therefore, we postulate that although delphinidin induces a splicing switch to promote 533  
the anti-angiogenic VEGF-A isoform expression, it is the inhibitory effect on VEGF-A 534  
expression that is the main factor contributing to its anti-angiogenic effect. Furthermore, 535  
delphinidin has been previous reported to be cytoprotective to endothelial function [36]. This 536  
may explain why we see a reno-protective effect of DIAVIT without any effect on blood 537  
glucose levels. 538  
In DN, glucotoxicity results in the increased generation of free radicals and oxidative 539  
stress [15]. Activation of NFĸB is widely reported to be evoked by increased oxidative stress 540  
[16]. Previous studies in rodent models of DN have indicated that a reduction in oxidative stress 541  
using anti-oxidants, such as those found in red berry extracts, resulted in decreased NFĸB 542  
activity, thus improving kidney function [17,18]. We show that DIAVIT prevented the 543  
increases in NFĸB expression within the kidney cortex of db/db mice, resulting in an inhibition 544  
of glomerular fibrosis and endothelial injury (Fig 6G). Furthermore, anothocyanins have been 545  
reported to protect against fibrosis, angiogenesis, and inflammation in the kidneys of diabetic 546  
animal models [37,38].  We summarize the potential mechanism of action of DIAVIT and 547  
delphinidin in DN using a flow diagram in Fig 8. 548  
 549  
Fig 8. Flow diagram describing the potential mechanism of DIAVIT and Delphinidin in 550  
type II DN 551  
High glucose and an increase in oxidative stress (ROS; reactive oxygen species) in the kidney 552  
results in increased phosphorylation of Akt. In turn this leads to activation of p65-NFĸB, 553  
resulting in the increased expression of pro-angiogenic and pro-fibrotic factors, which feed 554  
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back to further increase the activation of Akt. Akt activation also results in the phosphorylation 555  
of serine protein kinase 1 (SRPK1), leading to proximal splice site (PSS) selection in exon 8 556  
of the VEGF-A gene (pro-angiogenic VEGF-A165). DIAVIT acts to inhibit the phosphorylation 557  
of Akt and increase the expression of the SRPK1 inhibitor WT1. Furthermore, delphinidin acts 558  
to switch VEGF-A splicing, promoting distal splice site selection through the activation of 559  
SRSF6. This results in a reduction in fibrosis and angiogenesis in the diabetic kidney through 560  
p65-NFĸB and VEGF-A splicing. 561  
 562  
One limitation of this study was that we were unable to fully control the dose of 563  
DIAVIT given to the mice as it was added to the drinking water. Diabetic mice, on average, 564  
drank more water than the lean controls; as the levels of hyperglycaemia were similar in both 565  
db/db and db/db + DIAVIT mice, we estimated that they consumed approximately the same 566  
amount water. 567  
 568  
Conclusions 569  
In conclusion, we show that DIAVIT prevents increases in permeability and fibrosis in 570  
a mouse model of type II DN. One of the mechanisms by which DIAVIT, namely delphinidin, 571  
is acting are through switching VEGF-A splicing in the podocytes of the renal cortex. This 572  
study highlights the therapeutic potential of natural drugs and anthocyanins in DN through the 573  
manipulation of gene splicing and expression. Further studies are required to further deduce 574  
which other compound(s) in DIAVIT are having similar effects. 575  
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S1 Fig. Gas chromatography mass spectrometry (GC-MS) of the DIAVIT extract. To 691  
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generated the chromatogram observed in (A). (B) Mass spectrometry was carried out on each 693  
peak to sort the ions based on their mass-to-charge ratio. The extract was found to be extremely 694  
complex, with some chemical examples given. 695  
S2 Fig. Absolute urinary albumin creatinine ratio (uACR) values. *p<0.05 lean vs db/db, 696  
†p<0.05 db/db vs db/db + DIAVIT; Two-way ANOVA. 697  
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